Rheumatoid arthritis and cardiovascular risk: Between lights and shadows

Current Rheumatology Reviews

Volumn 9, Issue 2, 2013, Pages 100-104

  Bruzzese, Vincenzo ^a   Hassan, Cesare ^a   Ridola, Lorenzo ^a   Zullo, Angelo ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Cardiovascular disease; Meta analysis; Rheumatoid arthritis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN; HLA DRB1 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DRUG USE; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; OBESITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE;

EID: 84882771367     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573397111309020004     Document Type: Article

References (39)

1. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52 (2): 412-420.
2. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007; 46 (2): 350-357.
3. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-411.
4. Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis 2011; 70 (6): 881-883.
5. Santos MJ, Vinagre F, Canas da Silva J, et al. Cardiovascular risk profile in systemic lupus erythematous and rheumatoid arthritis: a comparative study of female patients. Acta Rheumatol Port 2010; 35 (4): 325-332.
6. Funk CD, Fitzgerald GA. COX-2 inhibitors and cardiovascular risk. Cardiovasc Pharmacol 2007; 50 (5): 470-479.
7. Gabriel SE, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24 (2): 171-6.
8. Gerli R, Sherer Y, Vaudo G, et al. Early atherosclerosis in rheumatoid arthritis: effects of smoking on thickness of the carotid artery intima media. Ann NY Acad Sci 2005; 1051 (6): 281-90.
9. Bartoloni E, Alunno A, Bistoni O, et al. How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 2010; 9 (10): 701-7.
10. Ku IA, Imboden JB, Hsue PY, et al. Rheumatoid arthritis: a model of systemic inflammation driving atherosclerosis. Circ J 2009; 73 (6): 977-85.
11. Bisoendial RJ, Stroes ESG, Tak PP. Critical determinants of cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2011; 17 (1): 21-6.
12. Gonzales-Gay MA, Gonzales-Juanatey C, Ollier WE. Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmun Rev 2004; 3 (4): 301-4.
13. Rodriguez-Rodriguez L, Lopez-Mejias R, Garcia-Bermudez M, Gonzalez-Juanatey C, Gonzalez-Gay MA, Martin J. Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012; 2012: 574817. doi: 10.1155/2012/574817. Epub 2012 Aug 2.
14. Abou-Raya A, Abou Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006; 5 (5): 331-7.
15. Nakamura M, Yoshida H, Arakawa N, et al. Effects of Tumor Necrosis Factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J Cardiovasc Pharmacol 2000; 36 (4): 487-92.
16. Molenaar ET, Voskuil AE, Familian A, et al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001; 44 (5): 997-1002.
17. Koshy M, Berger D, Crown MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98 (3): 826-37.
18. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110 (17): 2552-8.
19. Sherer Y, Shoenfeld Y. Mechanism of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2 (2): 99-106.
20. Tsimilkas S, Brilakis ES, Lennon RJ, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery and cardiovascular events. J Lipid Res 2007; 48 (2): 425-33.
21. Lewis MJ, Malik TH, Ehrenstein MR, et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120 (5): 417-26.
22. Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10 (4): 213.
23. Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012; 64 (6): 1828-37.
24. Herbrig K, Haensel S, Oelschlaegel U, et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 2006; 65 (2): 157-63.
25. George J, Meroni PL, Gilburd B, et al. Anti-endothelial cell antibodies in patients with coronary atherosclerosis. Immunol Lett 2000; 73 (1): 23-7.
26. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Eng J Med 1999; 340 (1): 15-22.
27. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297 (12): 1344-53.
28. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115 (4): 459-67.
29. Tyrrell PN, Beyene J, Feldman BM, et al. Rheumatic disease and carotid intimamedia thickness. A systematic review and metaanalysis. Arterioscler Thromb Vasc Biol 2010; 30 (5): 1014-26.
30. Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009; 48 (10): 1309-13.
31. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a metaanalysis of observational studies. Ann Rheum Dis 2012; 71 (9): 1524-9.
32. Peters MJL, van Halm V, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61 (11): 1571-9.
33. Protogerou A, Zampeli E, Tentolouris N, et al. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study. Ann Rheum Dis 2012; 71 (9): 1534-6.
34. Zampeli E, Protogerou A, Stamatelopoulos K, et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012; 14 (2): R44. doi: 10.1186/ar3757.
35. Bruzzese V, Marrese C, Zullo A, et al. Carotid artery intima-media thickness in patients with autoimmune connective tissue diseases: a case-control study. Intern Emerg Med 2011 Oct 28.[Epub ahead of print]
36. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 2001; 44 (6): 1467-9.
37. Ross JS, Madigan D, Hill KP, et al. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009; 169 (21): 1976-85.
38. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007; 102 (3): 662-7.
39. Catarzi S, Favilli F, Romagnoli C, Marcucci T, Picariello L, Tonelli F. Oxidative state and IL-6 production in intestinal myofibroblasts of Crohn's disease patients. Inflamm Bowel Dis 2011; 17 (8): 1674-84.